BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 36872366)

  • 21. Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors.
    Jaiswal BS; Janakiraman V; Kljavin NM; Eastham-Anderson J; Cupp JE; Liang Y; Davis DP; Hoeflich KP; Seshagiri S
    PLoS One; 2009 May; 4(5):e5717. PubMed ID: 19492075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
    Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS
    Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAF
    Grasso M; Estrada MA; Ventocilla C; Samanta M; Maksimoska J; Villanueva J; Winkler JD; Marmorstein R
    ACS Chem Biol; 2016 Oct; 11(10):2876-2888. PubMed ID: 27571413
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions.
    King AJ; Arnone MR; Bleam MR; Moss KG; Yang J; Fedorowicz KE; Smitheman KN; Erhardt JA; Hughes-Earle A; Kane-Carson LS; Sinnamon RH; Qi H; Rheault TR; Uehling DE; Laquerre SG
    PLoS One; 2013; 8(7):e67583. PubMed ID: 23844038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.
    Peng SB; Henry JR; Kaufman MD; Lu WP; Smith BD; Vogeti S; Rutkoski TJ; Wise S; Chun L; Zhang Y; Van Horn RD; Yin T; Zhang X; Yadav V; Chen SH; Gong X; Ma X; Webster Y; Buchanan S; Mochalkin I; Huber L; Kays L; Donoho GP; Walgren J; McCann D; Patel P; Conti I; Plowman GD; Starling JJ; Flynn DL
    Cancer Cell; 2015 Sep; 28(3):384-98. PubMed ID: 26343583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protein kinase C alpha trigger Ras and Raf-independent MEK/ERK activation for TPA-induced growth inhibition of human hepatoma cell HepG2.
    Wen-Sheng W
    Cancer Lett; 2006 Jul; 239(1):27-35. PubMed ID: 16169661
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines.
    Balmanno K; Chell SD; Gillings AS; Hayat S; Cook SJ
    Int J Cancer; 2009 Nov; 125(10):2332-41. PubMed ID: 19637312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Scaffolding mechanism of arrestin-2 in the cRaf/MEK1/ERK signaling cascade.
    Qu C; Park JY; Yun MW; He QT; Yang F; Kim K; Ham D; Li RR; Iverson TM; Gurevich VV; Sun JP; Chung KY
    Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34507982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.
    Montagut C; Sharma SV; Shioda T; McDermott U; Ulman M; Ulkus LE; Dias-Santagata D; Stubbs H; Lee DY; Singh A; Drew L; Haber DA; Settleman J
    Cancer Res; 2008 Jun; 68(12):4853-61. PubMed ID: 18559533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting CRAF kinase in anti-cancer therapy: progress and opportunities.
    Wang P; Laster K; Jia X; Dong Z; Liu K
    Mol Cancer; 2023 Dec; 22(1):208. PubMed ID: 38111008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
    Joseph EW; Pratilas CA; Poulikakos PI; Tadi M; Wang W; Taylor BS; Halilovic E; Persaud Y; Xing F; Viale A; Tsai J; Chapman PB; Bollag G; Solit DB; Rosen N
    Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14903-8. PubMed ID: 20668238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors.
    Ming Z; Lim SY; Kefford RF; Rizos H
    Pigment Cell Melanoma Res; 2020 Mar; 33(2):345-357. PubMed ID: 31518489
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models.
    Del Curatolo A; Conciatori F; Cesta Incani U; Bazzichetto C; Falcone I; Corbo V; D'Agosto S; Eramo A; Sette G; Sperduti I; De Luca T; Marabese M; Shirasawa S; De Maria R; Scarpa A; Broggini M; Del Bufalo D; Cognetti F; Milella M; Ciuffreda L
    J Exp Clin Cancer Res; 2018 Jul; 37(1):140. PubMed ID: 29986755
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation.
    Heard JJ; Phung I; Potes MI; Tamanoi F
    BMC Cancer; 2018 Jan; 18(1):69. PubMed ID: 29320991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
    Hatzivassiliou G; Song K; Yen I; Brandhuber BJ; Anderson DJ; Alvarado R; Ludlam MJ; Stokoe D; Gloor SL; Vigers G; Morales T; Aliagas I; Liu B; Sideris S; Hoeflich KP; Jaiswal BS; Seshagiri S; Koeppen H; Belvin M; Friedman LS; Malek S
    Nature; 2010 Mar; 464(7287):431-5. PubMed ID: 20130576
    [TBL] [Abstract][Full Text] [Related]  

  • 36. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
    Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
    Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.
    Henry JR; Kaufman MD; Peng SB; Ahn YM; Caldwell TM; Vogeti L; Telikepalli H; Lu WP; Hood MM; Rutkoski TJ; Smith BD; Vogeti S; Miller D; Wise SC; Chun L; Zhang X; Zhang Y; Kays L; Hipskind PA; Wrobleski AD; Lobb KL; Clay JM; Cohen JD; Walgren JL; McCann D; Patel P; Clawson DK; Guo S; Manglicmot D; Groshong C; Logan C; Starling JJ; Flynn DL
    J Med Chem; 2015 May; 58(10):4165-79. PubMed ID: 25965804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Receptor-Driven ERK Pulses Reconfigure MAPK Signaling and Enable Persistence of Drug-Adapted BRAF-Mutant Melanoma Cells.
    Gerosa L; Chidley C; Fröhlich F; Sanchez G; Lim SK; Muhlich J; Chen JY; Vallabhaneni S; Baker GJ; Schapiro D; Atanasova MI; Chylek LA; Shi T; Yi L; Nicora CD; Claas A; Ng TSC; Kohler RH; Lauffenburger DA; Weissleder R; Miller MA; Qian WJ; Wiley HS; Sorger PK
    Cell Syst; 2020 Nov; 11(5):478-494.e9. PubMed ID: 33113355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic strategies for targeting BRAF in human cancer.
    Pratilas CA; Solit DB
    Rev Recent Clin Trials; 2007 May; 2(2):121-34. PubMed ID: 18473997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRAFV600E negatively regulates the AKT pathway in melanoma cell lines.
    Chen B; Tardell C; Higgins B; Packman K; Boylan JF; Niu H
    PLoS One; 2012; 7(8):e42598. PubMed ID: 22880048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.